Publication|Articles|January 21, 2026

Supplements and Featured Publications

  • Redefining Hemophilia Management: Treatment Goals, Nonfactor Replacement Therapies, and the Role of Fitusiran

Participating Faculty: Redefining Hemophilia Management: Treatment Goals, Nonfactor Replacement Therapies, and the Role of Fitusiran

Listen
0:00 / 0:00

Faculty

Steven W. Pipe, MD

Professor of Pediatrics and Pathology

University of Michigan

Ann Arbor, MI

Faculty Disclosures

The following have relevant commercial financial relationships or affiliations to disclose:

Steven W. Pipe, MD, reports the following relevant commercial financial relationships or affiliations in the past 12 months:

CONSULTANCIES OR PAID ADVISORY BOARDS

Bayer, BioMarin, Chugai, CSL Behring, HEMA Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Roche/Genentech/Spark Therapeutics, Sanofi, Star Therapeutics, and Takeda

LECTURE FEES AT THE INVITATION OF A COMMERCIAL SPONSOR

Chugai, Roche, Sanofi

MEETING/CONFERENCE ATTENDANCE

Sanofi

SCIENTIFIC ADVISORY BOARDS

Equilibra, GeneVentiv